Over the weekend, more than 286,000 doses of the vaxzevria brand of the AstraZeneca vaccine from Norway arrived in the country. But sections raised concern considering that the donor country has suspended the use of the same jab in their country over studies that connected the drug to a rare type of blood clots.
Ministers attending an Inter- Africa Health Ministers meeting chaired by Uganda’s Dr. Jane Ruth Aceng expressed displeasure over the move calling it another of the vaccine capitalism that has become rampant with scarce COVID-19 jabs.
“This is an important moment of global solidarity and a critical milestone in the push to ensure those most at risk, everywhere are protected,” said Dr Seth Berkley, the CEO of Gavi, the Vaccine Alliance (Gavi) in a statement.
This is the fifth supply agreement UNICEF has signed for COVID-19 vaccines on behalf of the COVAX facility following previously announced agreements with the Serum Institute of India, Pfizer and AstraZeneca. The agreements have enabled the facility to make deliveries of the vaccine to the 92 countries that they cover.
According to a new statement, the rollout of the drug will commence with the successful negotiation and execution of supply agreements which will add on to an existing agreement with Serum Institute of India (SII) in which the facility booked 100 million doses of the AstraZeneca vaccine.